Size exclusion chromatography (SEC) is a well-established analytical method for quantitative and qualitative aggregate analysis of monoclonal antibodies (mAbs) and other related biotherapeutics. However, because SEC is a non-adsorptive separation modality, it may be unclear as to which method parameters to adjust for the optimal separation of monomer, aggregate, and fragment.

In this presentation, we discuss SEC method experimental design space. Column selection, mobile phase, flowrate, and injection volume are all discussed to ensure optimal separation of monomer, aggregate, and fragment of mAbs and other mAb formats.

Webinar Learning Objectives:

Learn about a breakthrough in SEC column development to improve method robustness for monoclonal antibodies and related recombinant proteins
Understand how column choice‑including exclusion limit, particle size, and column length may affect chromatographic performance
Determine a practical mobile phase screen to optimize mAb aggregate recovery, fragment separation and understand when organic solvent should be used and how other co-solvents may be beneficial in improving peak shape and recovery

Helen Whitby PhD

Senior Product Manager, Biopharma, Phenomenex

Appearances